Gilead Sciences Interest Expense 2011-2026 | GILD

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Gilead Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
-1 M	-2 M	944 M	935 M	1 B	984 M	995 M	1.08 B	1.12 B	964 M	688 M	412 M	307 M	361 M	205 M	109 M	69.7 M	65.2 M	63.2 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.12 B	-2 M	542 M

Quarterly Interest Expense Gilead Sciences

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1	2010-Q3	2010-Q2	2010-Q1	2009-Q3	2009-Q2
-2 M	-1 M	-6 M	4 M	-	-4 M	1 M	-4 M	-	232 M	230 M	230 M	-	229 M	242 M	238 M	-	250 M	256 M	257 M	-	236 M	240 M	241 M	-	250 M	248 M	254 M	-	264 M	266 M	290 M	-	291 M	269 M	261 M	-	242 M	227 M	230 M	-	165 M	140 M	153 M	-	104 M	102 M	76 M	-	73.9 M	78 M	81.8 M	-	89.3 M	88.4 M	97.3 M	-	43.1 M	46.1 M	41.2 M	33.6 M	17.8 M	17 M	17.2 M	18.5 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
291 M	-6 M	146 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Coherus BioSciences CHRS	9 M	$ 1.37	-3.17 %	$ 160 M	USA
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Alpine Immune Sciences ALPN	98 K	-	-	$ 2.17 B	USA
ASLAN Pharmaceuticals Limited ASLN	442 K	-	-14.27 %	$ 1.7 M	Singapore
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 49.84	-3.19 %	$ 4.48 B	Schweiz
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Celldex Therapeutics CLDX	927 K	$ 29.36	-0.81 %	$ 1.95 B	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 2.9	-2.03 %	$ 4.77 M	Israel
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 23.33	2.37 %	$ 2.97 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA